Clinical Trial

Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults

Study acronym: CORSAR
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Septic arthritis is a severe infection associated with significant morbidity and mortality. Despite eradication of the microorganisms, persistent inflammation may lead to substantial long-term functional joint sequelae. The use of corticosteroids could reduce this inflammation, thereby improving functional joint outcomes and facilitating first-line medical treatment. The hypothesis of this study is that corticosteroid administration, in addition to antibiotic therapy, reduces persistent inflammation and improves functional joint prognosis in adult patients with acute septic arthritis.
Trial Details
NCT Number NCT07440238
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Septic Arthritis
Enrollment 200 participants
Start Date 2026-03-30
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-27